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ABSTRACT:
The receptor for the urokinase plasminogen activator (uPAR) is up-regulated in 
malignant tumors. Historically the function of uPAR in cancer cell invasion is strictly 
related to its property to promote uPA-dependent  proteolysis of extracellular matrix 
and to open a path to malignant cells. These features are typical of mesenchymal 
motility. Here we show that the full-length form of uPAR is required when prostate 
and melanoma cancer cells convert their migration style from the “path generating” 
mesenchymal to the “path finding” amoeboid one, thus conferring a plasticity to tumor 
cell invasiveness across three-dimensional matrices. Indeed, in response to a protease 
inhibitors-rich milieu, prostate and melanoma cells activated an amoeboid invasion 
program connoted by retraction of cell protrusions, RhoA-mediated rounding of the 
cell body, formation of a cortical ring of actin and a reduction of Rac-1 activation. 
While the mesenchymal movement was reduced upon silencing of uPAR expression, 
the amoeboid one was almost completely abolished, in parallel with a deregulation of 
small Rho-GTPases activity. In melanoma and prostate cancer cells we have shown 
uPAR colocalization with β1/β3 integrins and actin cytoskeleton, as well integrins-
actin co-localization under both mesenchymal and amoeboid conditions. Such co-
localizations were lost upon treatment of cells with a peptide that inhibits uPAR-
integrin interactions. Similarly to uPAR silencing, the peptide reduced mesenchymal 
invasion and almost abolished the amoeboid one. These results indicate that full-
length uPAR bridges the mesenchymal and amoeboid style of movement by an inward-
oriented activity based on its property to promote integrin-actin interactions and the 
following cytoskeleton assembly. 
INTRODUCTION  
Cancer cells move within tissues collectively or as 
single cells. In collective invasion inter-cellular cohesion 
in form of strands, sheets,  amorphous masses or more 
or less regularly shaped tubes is required during the 
invasion process [1]. While collective movement has been 
associated with tumor cell entry into the open lymphatic 
vessels, the movement of individual cells is required for 
cancer cells to sneak across basement membranes, to enter 
the bloodstream and disseminate to distant organs [2]. The 
invasion strategy of single tumor cells develops according 
to at least two distinct modes of migration: the so-called 
elongated-mesenchymal mode and rounded-amoeboid 
mode. The mesenchymal migration requires the activity 
of extracellular matrix (ECM) degrading proteases, 
while amoeboid motility is an opportunistic movement, 
which allows cells to glide through, rather than degrade, 
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ECM barriers, using movements based on adaptations 
of the cell body. The mesenchymal movement depends 
on Rac-driven actin cytoskeleton contractility, while the 
amoeboid one relies on Rho-ROCK-dependent regulation 
of cortical actin to generate cortical tension, stiffness and 
the maintenance of roundish cell morphology [3]. Single 
“default” migration styles are preferentially employed  by 
a particular cell, such as the amoeboid  for leukocytes, the 
mesenchymal for stromal cells, the collective for epithelial 
cell sheets [2]. The most widespread mean to promote 
an amoeboid movement pattern in cancer cells cultured 
in vitro is to create an artificial environment where cells 
must cope with a mixture of protease inhibitors [4]. Little 
is known about physiological inducers of amoeboid 
motility. In many experimental examples, mesenchymal-
to-amoeboid transition (MAT) depends on pathways that 
weaken Rac and/or strengthen Rho/ROCK signalling 
[1-5]. Epigenetic expression of regulating factors seems 
to be important. In particular, pathways that activate 
Rho lead to MAT, including inhibition of negative Rho 
regulators [6] or the activation of Ephrin2A receptor 
tyrosine kinase signalling [7]. Among environmental 
conditions, an interesting paper has highlighted the role 
of matrix-bound plasminogen inhibitor type-1 (PAI-1) 
in supporting amoeboid movement and cell blebbing of 
human colorectal cancer cells via RhoA/ROCK1 signaling 
[8].
Experimental evidences accumulated over the last 
25 years connote the receptor for the urokinase-type 
plasminogen activator (uPAR) as the prototype receptor 
regulating the mesenchymal style of cell movement 
by triggering pericellular proteolysis of invasive cells. 
Plasmin generated  following the direct activation of 
plasminogen by uPAR-bound urokinase plasminogen 
activator (uPA) opens a path to invasive cells by both 
direct and pro-matrix-metallo-proteinases (MMPs)-
activation-dependent degradation of ECM. Besides 
plasmin-generation-dependent activities uPAR also shows 
proteolysis-independent functions. Such properties entail 
uPAR interaction with vitronectin (VN) and integrins, able 
to provide a foothold to moving cells [9]. In particular, 
uPAR interaction with integrins has been shown to 
increase integrin affinity for ECM ligands [10]. Besides 
outward-oriented activities, uPAR is also involved in the 
regulation of the actin cytoskeleton and cell motility [11]. 
Due to its glycosyl-phosphatidyl-inositol (GPI)-anchor 
attachment [12], uPAR is devoid of a cytoplasmic domain, 
a feature that renders uPAR incapable of signalling. This 
characteristic requires membrane partners enabling uPAR 
to deliver signals that propagate to the cell contractile 
apparatus. Most consistently uPAR has been found 
associated with integrins [11,13,14].  Besides interaction 
with ECM ligands, integrins provide a molecular link 
that connects microenvironment to the cytoskeleton. 
Together with a long series of adaptor proteins  integrins 
define molecular mechanical pathways in cells, which 
subsequently determine actin dynamics and cell 
movement [15]. Thus, a major pathway that controls in-
ward integrin activity may define and distinguish cancer 
cell invasion strategies. On these considerations, uPAR 
appears a good candidate molecule capable of modulating 
integrin function and to sustain the style of movement of 
a cell. Here we show that uPAR bridges the mesenchymal 
and amoeboid style of movement in a series of prostate 
carcinoma and melanoma cell lines, by its property to 
warrant the integrin-mediated connection between actin 
cytoskeleton and the cell membrane. 
RESULTS
Function of uPAR in mesenchymal invasion of 
tumor cells
uPAR is expressed by cells that move in a 
mesenchymal fashion. uPAR-bound uPA promotes 
plasminogen activation to plasmin and subsequent pro-
MMPs activation-dependent ECM degradation. To verify 
the role of uPAR in the mesenchymal movement we 
measured uPAR by a quantitative Real-Time PCR and 
Western Blotting analysis showing that uPAR expression 
was proportional to the number of invasive cells in the 
Boyden chamber-Matrigel invasion assay (figures 1A, 1B 
and 1C). Blocking uPAR mesenchymal function with an 
antibody (R3) against uPAR domain-1, thereby masking 
the uPA binding site, resulted into a decrease of invasion 
which was similar in all the examined cancer cell lines 
(figure 1D). The use of the blocking antibody blunted 
the uPAR-dependent proteolytic cascade without using 
protease inhibitors. In the absence of protease inhibitors 
the pre-specified movement style of single migrating 
cancer cells is the mesenchymal one [2]. 
Induction of the amoeboid phenotype
Matrigel invasion, Rac1/RhoA activation and cell 
morphology. To evaluate whether exposure to a protease 
inhibitors cocktail induced a protease-independent 
invasion, we  subjected cancer cell lines to a Boyden 
chamber migration assay through a thick Matrigel coating, 
in the presence of the inhibitor cocktail added to the cell 
suspension and to Matrigel solution before polymerization. 
The percent amoeboid response of each cell line with 
respect to the mesenchymal control was not comparable 
in terms of invasive cells, ranging from 30% to 72% 
depending on the cancer cell line, indicating that plasticity 
of cell migration upon variation of microenvironment 
conditions is greatly variable among cancer cells (figure 
2A). The experimental conditions here referred to as 
“amoeboid” were characterized by a residual proteolytic 
activity that did not account for the size of the invasive 
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Figure 1: uPAR expression and function in mesenchymal invasion of prostate cancer and melanoma cells. Panel A: 
Quantitative Real-Time PCR of uPAR in melanoma and prostate cancer cell lines. Results are the mean of three different experiments ± 
SD. * : p<0.05 with respect to LNCaP and MEWO cells, respectively. Panel B: Western Blotting analysis of uPAR in prostate cancer and 
melanoma cell lines. Numbers on the right refer to molecular weights expressed in kDa. GAPDH used as a reference loading control. Panel 
C: invasion of porous filters coated with a 3D Matrigel layer, showing the differential total number of invading cells/filter for each one of 
the used cell lines. Panel D: activity of  the R3 uPAR-blocking antibody on Matrigel invasion. The pictures show the typical appearance of 
filters in the absence and in the presence of the R3 antibody for each cell line. Results are the mean of three different experiments ± SD. * 
: p<0.05 with respect to LNCaP and MEWO cells (panel B), or with respect to control (panel C), respectively.
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Figure 2:Induction of the amoeboid movement in prostate cancer and melanoma cells. Panel A: the histogram on the left 
shows invasion of porous filters coated with a 3D Matrigel layer, expressed as % cells moving under amoeboid conditions for each one 
of the cell lines. Refer to figure 1 for the absolute number of invading cells under mesenchymal conditions. Mix: presence of the protease 
inhibitors cocktail. Results are the mean of five different experiments performed in triplicate on each cell line ± SD. * : p<0.05.  The 
histogram on the right shows the collagenolytic activity of Pcb1 and A375M6 cells under mesenchymal and amoeboid conditions, expressed 
as % collagen degradation with respect to the positive control obtained by addition of exogenous collagenase. Ctrl-: collagenolytic activity 
in the absence of cells and of added exogenous collagen; Ctrl+: collagenolytic activity in the absence of cells but in the presence of 
exogenous collagenase. Results are the mean of two different experiments performed in triplicate on each cell line ± SD. * : p<0.05. Panel 
B: Western blotting of total and GTP-loaded forms of small Rho-GTPases RhoA and Rac1 under mesenchymal and amoeboid conditions 
for each prostate cancer and melanoma cell line. Three experiments were performed for each cell line in each condition. Histograms report 
band densitometry; * indicates statistical significance at p<0.05. Numbers on the right refer to molecular weights expressed in kDa. Rac1-
GTP and RhoA-GTP, GTP-loaded forms of small Rho GTP-ases; Rac1 and RhoA, total un-loaded forms of small Rho GTP-ases, used as 
a reference loading control. 
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cell population (figure 2A). To characterize the motility 
shift  we also analyzed the activation of two recognized 
regulators of the cytoskeleton, the small GPTases RhoA 
and Rac1, and cell morphology, as related to actin 
organization. Mesenchymal motility has been recognized 
to be causally linked to activation of Rac, which drives 
motility by promoting lamellipodia and filopodia, 
and inhibition of Rho GTPases, whereas an opposite 
phenotype has been associated with amoeboid motility 
[16,17]. Western blotting data for the activated forms 
of RhoA and Rac1, compared to total RhoA and Rac1, 
provided univocal results for all the examined cell lines, 
showing a decrease of activated Rac1 and an increase of 
activated RhoA upon shifting of cells to the amoeboid 
movement (figure 2B). The overall morphology of the 
cell and its dependency on actin cytoskeleton assembly 
is characteristic of the movement style. Mesenchymal 
motility is connoted by an elongated, fibroblast-like, cell 
morphology with established cell polarity, dependent on 
the small GTPase Rac which, in turn, organizes actin 
polymerization to form filopodia and lamellipodia [18], 
giving origin to actin-rich protrusions. These features were 
exhibited by cancer cells under control conditions. Under 
the spur of protease inhibition all the cell lines acquired a 
round morphology and a sub-membranous cortical actin 
localization, features connoting the amoeboid movement 
(figure 3). The WST-1 assay showed that viable cells were 
more that 95% under both control and protease inhibitors 
Figure 3:Morphological features of the mesenchymal 
(elongated) to amoeboid (roundish) transition  (MAT) 
of prostate cancer and melanoma cells.  Each picture 
shows the general pattern and related magnification of a small 
field for each cell line. Red: phalloidin staining of the actin 
cytoskeleton. Blue: nuclear staining with DAPI. Magnification 
40 X for reference pictures and 100 X for enlarged insets. 
Results shown are representative of two different preparations 
of each cell line under mesenchymal and amoeboid conditions. 
Round cells, perinuclear cortical actin localization and the loss 
of actin-rich filopodia are evident in amoeboid conditions.
Antibody Cells line & treatment
Colocalization 
coefficient (M2)
Anti-uPAR+Phalloidin M6 ctrl 0,901
Anti-uPAR+Phalloidin M6 + M25 0,283
Anti-uPAR+Phalloidin M6 + mix 0,803
Anti-uPAR+Phalloidin M6 + M25 + mix 0,250
Anti-uPAR+Phalloidin Pcb1 ctrl 0,853
Anti-uPAR+Phalloidin Pcb1 + M25 0,265
Anti-uPAR+Phalloidin Pcb1 + mix 0,745
Anti-uPAR+Phalloidin Pcb1 + M25 + mix 0,293
Anti-uPAR+Anti-Integrin β3 M6 ctrl 0,798
Anti-uPAR+Anti-Integrin β3 M6 + mix 0,713
Anti-uPAR+Anti-Integrin β1 Pcb1 ctrl 0,848
Anti-uPAR+Anti-Integrin β1 Pcb1 + mix 0,732
Anti-uPAR+Anti-Integrin β3 M6 ctrl 0,979
Anti-uPAR+Anti-Integrin β3 M6 + M25 0,542
Anti-uPAR+Anti-Integrin β3 M6 + mix 0,866
Anti-uPAR+Anti-Integrin β3
M6 + M25 
+ mix 0,433
Anti-uPAR+Anti-Integrin β1 Pcb1 ctrl 0,796
Anti-uPAR+Anti-Integrin β1 Pcb1 + M25 0,152
Anti-uPAR+Anti-Integrin β1 Pcb1 + mix 0,634
Anti-uPAR+Anti-Integrin β1
Pcb1 + M25 
+ mix 0,230
Anti-uPAR+Phalloidin HEK uPAR 293 0,771
Anti-uPAR+Phalloidin HEK uPAR 293 + mix 0,893
Anti-uPAR+Anti-Integrin β1
HEK uPAR 
293 0,731
Anti-uPAR+Anti-Integrin β1
HEK uPAR 
293 + mix 0,762
Anti-Integrin β3+Phalloidin M6 ctrl 0,968
Anti-Integrin β3+Phalloidin M6 + M25 0,589
Anti-Integrin β3+Phalloidin M6 + mix 0,984
Anti-Integrin β3+Phalloidin
M6 + M25 
+ mix 0,493
M25 concentration = 50uM
Table1
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treatment. Moreover, once re-incubated with an inhibitor 
cocktail-free medium, treated cells completely recovered 
their functional and morphological mesenchymal features 
(not shown).
Requirement of uPAR in amoeboid migration. 
Genetic uPAR knockdown has demonstrated robust 
antitumor activity both in vitro and in pre-clinical studies 
[19]. To induce the loss of uPAR function we used the 
uPAR-aODN previously used in other studies of our 
laboratory [20-22]. uPAR-aODN produced an evident 
reduction of uPAR expression inducing a strong decrease 
of mesenchymal and amoeboid movements (figure 4A 
and 4B). Both in control and in the presence of protease 
inhibitors all the cell lines showed a reduced active Rac1 
paralleled by an increased RhoA activation, while uPAR-
aODN treatment resulted into reduced Rac1 activation 
either in the absence or in the presence of the inhibitor 
cocktail. The RhoA/Rac1 ratio in the presence of aODN 
and aODN + inhibitor cocktail  conformed to the classical 
amoeboid pattern indicating a prevalence of RhoA activity 
in prostate cancer cell lines, while it showed smaller 
Figure 4: Effects of uPAR silencing with uPAR-aODN on invasion and small Rho-GTPases activation in mesenchymal 
and amoeboid conditions of prostate and melanoma cancer cells. Panel A: Western Blotting analysis of uPAR for each prostate 
cancer and melanoma cell line after  uPAR-aODN treatment. DOTAP: treatment of cells with the cationic liposome alone; aODN: treatment 
of cells with DOTAP liposomes-delivered uPAR-antisense oligodeoxynucleotide; sODN: treatment of cells with DOTAP liposomes-
delivered scramble oligodeoxynucleotide. Numbers on the right of each Western blotting refer to molecular weights expressed in kDa. 
GAPDH used as a reference loding control. Panel B: Matrigel invasion under mesenchymal (-MIX) and amoeboid (+MIX) conditions. 
Results are the mean of three experiments performed in triplicate on each cell line ± SD. * : p<0.05 with respect to controls. Panel C: 
Western blotting of total and GTP-loaded forms of small Rho-GTPases RhoA and Rac1 under mesenchymal and amoeboid conditions 
for each prostate cancer and melanoma cell line, untreated and treated with  aODN/sODN, respectively. Histograms report RhoA/Rac1 
ratio obtained by band densitometry quantification. *: statistical significance at p<0.05 with respect to control; **: statistical significance 
at p<0.01 with respect to controls . Numbers on the right of each Western blotting refer to molecular weights expressed in kDa. For other 
symbols, refer to the legend of figure 1.
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variations with respect to controls in melanoma cell lines 
(figure 4C). Therefore, under amoeboid conditions and 
in the presence of uPAR knockdown, cancer cells still 
activate ameoboid-related transductions but are unable 
to invade 3D matrices, indicating that the loss of uPAR 
is detrimental for both movement styles. The residual 
movement observed in the absence of protease inhibitors 
in control cells treated with uPAR-aODN must be ascribed 
to proteases of  different families.  
The full-length D1D2D3 form of uPAR is required 
to induce amoeboid migration. 
Native uPAR is organized in three differently folded 
homologous domains of about 90 amino acids each (D1, 
D2 and D3 from the N-terminus), stabilized by intra-
Figure 5: Mesenchymal and amoeboid features in HEK-293 cells transfected with intact uPAR (D1D2D3) and truncated 
uPAR (D2D3). Panel A: invasion of porous filters coated with a 3D Matrigel layer, showing the differential total number of invading cells/
filter under mesenchymal and amoeboid conditions, as reported in the text. +/-Mix: presence or absence of the protease inhibitors cocktail. 
Ilomastat: invasion in the presence of the MMP inhibitor. uPARD1D2D3:  HEK-293 cells transfected with intact uPAR; uPARD2D3: 
HEK-293 cells transfected with truncated uPAR; no uPAR: control cells transfected with an empty vector. Results are the mean of three 
different experiments performed in triplicate on each cell line ± SD. *: p<0.05 with respect to each control (first column of each histogram). 
Panel B: % collagenolytic activity of the uPARD1D2D3 transfectant under mesenchymal and amoeboid conditions, as described in the 
legend to figure 2. Ctrl-: collagenolytic activity in the absence of cells and of added exogenous collagen; Ctrl+: collagenolytic activity in 
the absence of cells but in the presence of exogenous collagen. Results are the mean of two different experiments performed in triplicate 
in each condition line ± SD. * : p<0.05. Panel C: Western blotting of total and GTP-loaded forms of small Rho-GTPases RhoA and Rac1 
under mesenchymal and amoeboid conditions for each HEK-293 transfectant. Three experiments were performed for each transfectant in 
each condition. Histograms report band densitometry, assuming 1 as the reference value of controls in each condition. * shows statistical 
significance at p<0.05. Panel D: Morphological features of the mesenchymal (elongated) to amoeboid (roundish) transition  (MAT) of each 
HEK-293 transfectant. Red: phalloidin staining of the actin cytoskeleton. Blue: nuclear staining with DAPI. Magnification:  200 X. Results 
shown are representative of two different preparations of each cell line under mesenchymal and amoeboid conditions. No-uPAR cells did 
not adhere under amoeboid conditions.
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molecular disulphide bonds [23]. The X-ray structure 
shows that uPAR binds uPA by directly interacting with 
D1, in a pocket built by all three domains [24]. These 
structural features suggest the necessity for cooperation 
of all three uPAR domains for high-affinity binding of 
uPA.  uPAR may be anchored to the cell surface either in 
its native form (D1D2D3) or in a truncated form (D2D3), 
as a result of a cleavage of the D1-D2 linker region [25]. 
The uPAR-negative human embrional kidney-293 (HEK-
293) cells transfected with cDNA of intact uPAR (uPAR-
D1D2D3), with cDNAs corresponding to the truncated 
form of uPAR (uPAR-D2D3) and with pcDNA3 empty 
vector (no-uPAR) [26] were used to evaluate whether 
the native D1D2D3 or the cleaved D2D3 form of uPAR 
was involved in uPAR-dependent amoeboid movement 
style. The three differentially transfected cell lines were 
capable of invading Matrigel-coated filters, while only 
the uPAR-D1D2D3 cell line showed invasion capabilities 
upon exposure to a protease inhibitor-rich environment 
(figure 5A). This indicates that the presence of full 
length uPAR is strictly required in order to shift from the 
mesenchymal to amoeboid movement style. Invasion in 
the absence of protease inhibitors also shows that Hek-
293 cells transfected with an empty vector (no-uPAR) and 
uPAR-D2D3 cells show similar invasion, although to a 
reduced level than uPAR-D1D2D3 (figure 5A on the left). 
Complete abolishment of invasion obtained in no-uPAR 
and in uPAR-D2D3 by Ilomastat treatment shows that 
Matrigel invasion of these cells is totally accounted for by 
MMPs, since it was inhibited by the MMPs inhibitor but 
not by the anti-uPAR R3 antibody (right panel of figure 
5A). Also in these cells collagenolysis was inhibited by the 
mix of protease inhibitors (figure 5B). Experiments aimed 
to evaluate small GTPases Rac1 and RhoA activation 
showed a decrease of activated Rac1 in the presence 
of protease inhibitors in all the transfectants, while a 
significant increase of RhoA activation was observed 
only in uPAR-D1D2D3 cells (figure 5C). Morphological 
study of actin assembly of the three cell lines plated 
on VN-enriched Matrigel-coated surfaces showed the 
presence of actin protrusions and an overall spindle-like 
morphology only in full-length uPAR-expressing cells, 
while an overall feature of round cells was similarly 
exhibited by no-uPAR  and uPAR-D3D3-expressing cells, 
which did not show actin protrusions (figure 5D).  In a 
protease inhibitor-rich milieu no-uPAR cells were unable 
to adhere, while the totality of uPAR-D1D2D3 and uPAR-
D2D3 cells assumed a round shape, lost actin filament 
protrusions and exhibited a rim of perinuclear cortical 
actin. Taken together, these data show that uPAR supports 
mesenchymal and amoeboid movement style only when 
expressed in its full-length native form.
Integrins bridge uPAR and actin cytoskeleton.
 Already established uPAR-mediated pathways 
include uPAR association with integrins, the key 
molecules that promote rearrangement of the actin 
cytoskeleton and cell movement.10 PCb1 cells, M6 
melanoma cells and the three HEK-293 clones show an 
integrin pattern in line with previous observations (figure 
6A) [26-30]. Confocal immuno-fluorescence analysis of 
integrin β1 and uPAR in PCb1 and of integrin β3 and 
uPAR in A375M6  cells is shown in figure 6C. These data 
show that uPAR-integrins interactions persist under both 
mesenchymal and amoeboid conditions. Treatment of 
cells with 50 μM peptide M25 for 2h at 37°C uncoupled 
uPAR from integrins while sM25 did not, in the absence 
and in the presence of the inhibitor cocktail (figure 6C). 
Immunoprecipitation experiments with lysates of Pcb1 and 
A375M6 cells demonstrated the activity of M25 peptide in 
uncoupling uPAR-integrin β1 or β3 interaction (figure 6B). 
The statistical analysis of uPAR-integrin co-localization 
for the cell lines considered in this study is reported in 
table 1. Parallel experiments aimed to evaluate uPAR-actin 
and integrins-actin colocalization showed that both uPAR 
and integrins co-localize with actin also in amoeboid 
conditions, where the thick ring of cortical actin/uPAR 
and cortical actin/integrin overlap (figure 7A). The use of 
peptide M25 uncoupled all the observed co-localizations 
(uPAR, integrins, actin) and produced structural alteration 
of actin which lost the stress fibres organization and 
acquired a granular feature under both mesenchymal and 
amoeboid conditions (figure 7B). The statistical analysis 
of uPAR-actin and integrin-actin co-localization for all the 
cell lines is reported in table 1.
Activity of the M25 peptide on mesenchymal 
and amoeboid migration styles and related 
transductions. 
On the basis of these results we reasoned that 
the property of M25 peptide to uncouple uPAR from 
integrins, and hence from actin under both mesenchymal 
and amoeboid conditions, could produce functional 
effects similar to those obtained with uPAR aODN on 
mesenchymal and amoeboid migration styles. Therefore 
we studied Matrigel invasion and Rac-1/RhoA modulation 
under each relevant experimental condition. Similarly to 
genetic uPAR knockdown, results of Matrigel invasion 
obtained on PCb1, A375 M6 and Hek-293 cells clearly 
show that M25 peptide exerts a very intense inhibition 
of the amoeboid movement of cells treated with the 
inhibitor cocktail and partially inhibits the movement of 
control cells that move with a pre-specified mesenchymal 
migration style (figure 8A). Results obtained on small 
Rho-GTPases  show that the shift from mesenchymal 
to amoeboid movement increases the RhoA/Rac1 ratio, 
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Figure 6: Integrin pattern and integrin-uPAR interaction. Panel A: semiquantitative RT-PCR of the shown integrin α and 
β chains in  the cell lines used in this study. GAPDH was used as a reference control. Products size, expressed in bp, are reported on 
the right. Panel B: immunoprecipitation of uPAR and β1-integrins in Pcb1 prostate carcinoma cells and of uPAR and β3-integrins in 
A375M6 melanoma cells. Input: Western blotting of aliquots of cell lysates before immunoprecipitation, used as a reference loading 
control. IP beta 1: immunoprecipitate obtained with anti-beta 1 antibodies; IB beta 1: immunoblotting with anti-beta 1 antibodies; IP beta 3: 
immunoprecipitate obtained with anti-beta 3 antibodies; IB beta 3: immunoblotting with anti-beta 3 antibodies; IB uPAR: immunoblotting 
with anti-uPAR antibody; IP uPAR: immunoprecipitate obtained with anti-uPAR antibodies. Molecular weights, expressed in kDa, are 
reported on the left. Panel C: confocal microscopy for uPAR (red fluorescence)-β1-integrins (green fluorescence) co-localization in Pcb1 
prostate carcinoma cells and for uPAR (red fluorescence)- β3-integrins (green fluorescence) co-localization in A375M6 melanoma cells 
under mesenchymal (control) and amoeboid (+MIX) conditions, in the absence and in the presence of M25 peptide and of scramble 
M25 peptide (sM25). Nuclear staining: DAPI (blue). The co-localization score is reported within each picture. Refer also to table 1 for a 
complete view of co-localization scores in all the examined cell lines. Magnification:  40 X. The shown pictures are representative of 50 
different pictures for each experimental condition that were studied by Image J analysis, as reported in the legend to table 1. 
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Figure 7: uPAR-actin co-localization. Panel A: confocal microscopy for uPAR (green fluorescence) and falloidin (red fluorescence), 
in A375-M6 melanoma cells under mesenchymal (control) and amoeboid (+MIX) conditions, in the absence of M25 peptide, and in the 
presence of M25 peptide or of its scramble counterpart (sM25). The co-localization score is reported within each figure, as well as in table 
1. Nuclear staining: DAPI (blue). Magnification: 40 X. The shown pictures are representative of 50 different pictures for each experimental 
condition that were studied by Image J analysis, as reported in the legend to table 1. Panel B:  Magnification (200 X) of selected sections of 
panel A to show actin cytoskeleton (revealed by red falloidin staining) derangement as an effect of M25 peptide treatment.
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even in the presence of M25 peptide (figure 8B), but 
such a Rho over-activation does not support amoeboid 
movement owing to the M25-dependent weakening 
of actin cytoskeleton-integrins-uPAR functional axis. 
Overall, the phenotypic effects obtained with the M25 
peptide are similar to those obtained with uPAR-aODNs, 
allowing us to conclude that uPAR regulates plasticity of 
cell movement in both the mesenchymal and amoeboid 
migration styles by an integrin-mediated coupling of the 
cell membrane to the actin cytoskeleton.
DISCUSSION
A ten years analysis of the prospective multicentre 
Chemo-N0 (node negative) trial  has identified the uPA/
uPAR system as the only level-of-evidence-1 cancer 
biomarker system for prognosis and/or prediction in node-
negative breast cancer [31]. uPAR contributes to multiple 
features of the malignant character, including high 
metastatic potential [32], angiogenesis [33], epithelial-
to-mesenchymal-transition (EMT) [34] and cancer cell 
stemness [35].  Our data show that uPAR has a role in 
sustaining both mesenchymal and amoeboid migration 
style of cancer cells by controlling the state of the actin 
cytoskeleton assembly via its integrin-mediated interaction 
with cytoskeleton.
 Far-off and recent studies have underlined the 
key role of multiple proteases and of their receptors in 
mesenchymal migration style of cancer cell during the 
invasion process so that the property of cancer cells to 
proteolytically degrade anatomical barriers has attained 
the role of a marker of cancer cell malignancy [36,37]. 
Amoeboid motility has been originally described in the 
amoeba Dictyostelium discoideum, but it is also exploited 
by eukaryotic cells under particular environmental cues, 
such as the need to rapidly slide through lose interstitial 
tissues with gaps that accommodate the cell body using 
flexible and weak adhesion sites, producing a movement 
that depends on dynamic cytoplasmic protrusions due 
to intracellular compartmentalization of  cytoplasm 
Figure 8: Phenotypic and biochemical effects of M25 treatment. Panel A: invasion of porous filters coated with a 3D Matrigel 
layer, by HEK-293 transfectants, Pcb1 and M6 cells under amoeboid and mesenchymal conditions, in the absence and in the presence of 
M25 peptide. Results are the mean of three different experiments performed in triplicate on each cell line ± SD. *: p<0.05. The pictures 
show the typical appearance of filters in each experimental condition. Panel B: Western blotting of total and GTP-loaded forms of small 
Rho-GTPases Rac1 and RhoA under mesenchymal and amoeboid conditions ± M25 peptide for each prostate cancer and melanoma cell 
line. Three experiments were performed for each cell line in different conditions. Histograms report RhoA/Rac1 ratio obtained by band 
densitometry quantification and * shows statistical significance at p<0.05. Numbers on the right of each Western blotting refer to molecular 
weights expressed in kDa. For other symbols, refer to the legend of figure 1.
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between an intact cortical actin cytoskeleton and the 
locally expanded cell membrane (blebs) [38]. Pioneer 
studies enlightened the possibility of cancer cells to move 
within tissues according to amoeboid features, leading 
to the so-called “cortical expansion model for amoeboid 
chemotaxis” of malignant cells [39]. Cancer cell amoeboid 
motility has now become an issue, accounting for  rapid 
movement of invading cells within the primary and the 
metastatic site. 
Herein we have shown that malignant cells derived 
from human melanoma and prostate cancer, as well as 
human embrional kidney 293 cells (HEK-293) transfected 
with the full-length form (D1D2D3) of the human 
uPAR, exhibit a uPAR-dependent mesenchymal invasion 
across a 3D Matrigel substrate, that is proportional to 
uPAR expression and that may be strongly reduced by 
preventing uPAR interaction with its ligand uPA, the 
observed residual mesenchymal Matrigel invasion being 
surely ascribable to the activity of multiple proteases. 
Our results indicate that the uPAR-driven proteolytic 
activity accounts for more that 50% of single migrating 
cells in all the studied cancer cell lines. The residual 
cell invasion has to be related to many other proteases 
such as members of the MMP and cathepsin families. 
Due to the high number of involved molecules it was 
not possible to use blocking antibodies, while the use of 
specific protease inhibitors could induce the shift to an 
amoeboid movement style. The same cells shifted  toward 
an amoeboid migration style (MAT) upon exposure to a 
protease inhibitor cocktail. Our observation that not the 
whole cancer cell populations undergo MAT and that the 
percentage of shifting cells varies among the different 
cell lines independently of their origin (primary tumor or 
metastasis) indicates that this feature is independent of 
cancer progression. Also small Rho-GTPases activation 
and cell morphology were consistent with MAT. Although 
under mesenchymal conditions not all the studied cell 
lines showed an unambiguously elongated cell shape, the 
acquisition of amoeboid features in the presence of the 
inhibitor cocktail, such as the attainment of a round shape 
and reorganization of actin according to a strictly sub-
cortical location were evident.  
The results obtained with uPAR-aODN on 
mesenchymal and amoeboid movement clearly show 
uPAR requirement in both styles of cancer cell migration. 
Moreover, the data obtained with HEK-293 cells 
transfected with the truncated or with the native form 
of uPAR show that only the full-length form supports 
amoeboid movement. Many proteases cleave the receptor 
(cleaved uPAR, c-uPAR) [40]. c-uPAR, devoid of D1, 
is unable to bind extracellular uPAR ligands, uPA and 
VN, as well as to interact with integrins, indicating that 
uPAR cleavage is a mechanism that negatively regulates 
uPAR activities associated with a migratory and invasive 
phenotype: in fact the full-length uPAR and uPA are 
up-regulated and are negative prognostic factors in 
several tumors [31]. In order to elucidate the mechanism 
whereby native uPAR regulates amoeboid movement, 
we decided to explore the in-ward uPAR activities by 
studying its property to regulate the actin cytoskeleton 
[10,11,26,41]. Interaction of uPAR with integrins is the 
foundation stone of the cell migration signalosome [10]. 
In our cancer cells we have confirmed uPAR interaction 
with β1 and β3 integrins by confocal microscopy and 
immunoprecipitation, showing that such interactions 
are present under both mesenchymal and amoeboid 
conditions. Integrins, which lack actin-binding domains, 
are indirectly connected to the actin cytoskeleton through 
different protein complexes that contain over a hundred 
different types of proteins, talin, α-actinin, filamin, 
tensin, parvin and myosin-X being the most studied, that 
transmit the mechanical force from the cell membrane to 
the actin cytoskeleton for cytoplasm contraction during 
cell movement [15].  We have shown herein that uPAR 
co-localizes with actin cytoskeleton in all the examined 
conditions, including the amoeboid one, where the thick 
ring of cortical actin and uPAR overlap. In the β-propeller 
model of α-chain folding, the sequence of the M25 peptide 
spans an exposed loop on the uPAR-binding surface of 
α-chain, thus impairing integrin-uPAR interaction [42]. 
M25 peptide not only uncoupled uPAR from integrins in 
all the cells and experimental conditions studied in this 
work, but it also produced a structural alteration of actin 
which lost the stress fibres and cortical organization under 
the mesenchymal and amoeboid conditions, and acquired 
a granular feature. It is therefore evident that M25 peptide 
uncouples uPAR from integrins, and hence from actin, 
thereby producing functional effects similar to those 
obtained with uPAR aODN on mesenchymal and amoeboid 
migration styles. The final effects of both treatments, that 
lead to an alteration of actin assembly, which is no longer 
efficiently bound to integrins modified by the loss of 
interaction with uPAR, result into a weakening of actin-
membrane coupling and in the loss of the tensile force 
that determines translocations of the cell body [15]. Actin 
disorganization impaired both mesenchymal and amoeboid 
migration of cancer cells. Also the activity of small Rho-
GTPases was deranged by the use of M25 peptide as well 
as by uPAR-aODN, thus partially inhibiting mesenchymal 
migration and totally inhibiting the amoeboid one. As the 
M25 peptide is specific for inhibition of uPAR-integrin 
α-chain interaction, its limited effects of on mesenchymal 
migration may be accounted for by the failure of the 
peptide to inhibit integrin-MMPs interactions that also 
regulate mesenchymal motility [43,44].
Available data indicate that a successful strategy to 
combat invasion and metastatic diffusion of aggressive 
cancer cells is the identification of molecular targets 
that control the ability of cancer cells to adapt to the 
environment by regulating plasticity of cancer cells. Taken 
together, the results obtained in the present study show 
that uPAR, a recognized marker of cancer cell progression, 
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is a molecular mediator of plasticity in cancer cell motility 
by regulating contractile forces in tumor cell migration 
through the functional axis uPAR-integrins-actin. Together 
with the many so far reported pro-tumoral activities of 
uPAR, our observations make the uPA/uPAR system an 
attractive target for the treatment of cancer that has not yet 
been extensively explored in the clinic [45].  
MATERIALS AND METHODS
Cell lines and culture conditions. 
Prostate cancer cell lines LNCaP and PC3 were 
purchased from ATCC (Manassas, VA, USA). LNCaP are 
androgen-sensitive human prostate adenocarcinoma cells, 
while PC3 cells, derived from a bone metastasis of a grade 
IV prostatic adenocarcinoma, are reported to be androgen 
receptor (AR)-negative. Pcb1 cell line, established from 
a bone metastasis of PC3, were provided by Professor 
Adriano Angelucci (L’Aquila, Italy). All prostate cancer 
cell lines were grown in RPMI-1640 culture medium 
(Euroclone, Milano, Italy) containing 2 mM glutamine, 
100 UI/ml penicillin, 100 µg/ml streptomycin and 
supplemented with 10% fetal bovine serum (FBS; 
Euroclone). Melanoma cell lines MeWo and A375 were 
purchased from ATCC.  A375 M6 cells, derived from 
a metastasis of A375, were provided by Professor Lido 
Calorini (Firenze, Italy). Melanoma cells were maintained 
in DMEM culture medium (Euroclone, Milano, Italy) 
containing 2 mM glutamine, 100 UI/ml penicillin, 100 
µg/ml streptomycin and supplemented with 10% FBS 
(Euroclone). uPAR-negative human embrional kidney 293 
(HEK-293) cells transfected with cDNA of intact uPAR 
(uPAR-D1D2D3), with cDNAs corresponding to the 
truncated form of uPAR (uPAR-D2D3) and with pcDNA3 
empty vector (no-uPAR), were kindly provided by 
Professor Pia Ragno (Napoli, Italy). HEK-293 transfected 
cells were grown in DMEM culture medium (Euroclone, 
Milano, Italy) containing 2 mM glutamine, 100 UI/ml 
penicillin, 100 µg/ml streptomycin and supplemented with 
10% fetal bovine serum (FBS; Euroclone). 
Quantitative Real-Time PCR analysis.
Total RNA was prepared using Nucleospin RNA II 
(Macherey-Nagel), agarose gel checked for integrity, and 
reverse transcribed with GoScript system (Promega) using 
random primers according to manufacturer’s instructions. 
uPAR expression in all cancer cell lines and after anti-
uPAR aODN treatment was determined by a quantitative 
Real-Time (RT)–PCR with an Applied Biosystem 7500 
Fast Real Time PCR System (Applied Biosystems, 
Milano, Italy) and determined by the comparative Ct 
method using 18S ribosomal RNA as the normalization 
gene. Amplification was performed with the default PCR 
setting: 40 cycles of 95°C for 15 seconds and of 60°C for 
60 seconds using SYBR Green–based detection (GoTaq 
qPCR Master Mix; Promega). Primers (IDT, Tema Ricerca, 
Italy) used for RT-PCR were as follows:  -18S-rRNA: 
sense, 5’-CCAGTAAGTGCGGGTCATAAG-3’ antisense, 
5’-GCCTCACATAACCATCCAATC-3’; 
-uPAR: sense, 5’- 
GCCCAATCCTGGAGCTTGA-3; antisense, 5’- 
TCCCCTTGCAGCTGTAACACT-3’. 
Semiquantitative reverse transcription–
polymerase chain reaction (PCR) analysis.
Total RNA preparation and reverse transcription 
were performed as previously reported [20].  The levels of 
messenger RNA for the integrin chains were determined 
by an internal-based semiquantitative RT-PCR, using 
procedures and primers previously described [13]. 
3D-invasion assay with Boyden chambers.
 Invasion was studied in Boyden chambers in which 
the upper and lower wells were separated by 8µm–pore 
size polycarbonate filters coated with Matrigel (BD 
Biosciences). In order to increase uPAR dependency of the 
invasion process, the Matrigel was enriched with human 
VN (Sigma-Aldrich, cat. V8379), to a final concentration 
of 300 μg/ml. To obtain a “thick” layer, we added 100 
μl of Matrigel/cm2 porous membrane. According to the 
manufacturer’s instruction such an amount results into a 
500 μm thick Matrigel layer, corresponding to about 25 
folds the average diameter of circulating prostate and 
melanoma cells [46,47]. Cancer cells (25 x 103) were 
placed in the upper well of the Boyden chamber, and 
invasion was performed at 37 °C in 5% CO2 for 12 hours, 
a time consistent with the average speeds of cell migration 
under amoeboid and mesenchymal conditions in 500 μm 
thick gels [2]. To evaluate the uPAR-dependent invasion, 
some experiments were performed in the presence of anti-
uPAR R3 antibody which blocks uPA/uPAR interaction 
(American Diagnostica) or irrelevant IgG (all used at 
1.5 μg/ml) or after anti-uPAR aODN treatment. Invasion 
quantified as previously described [21,22].
Induction of the amoeboid phenotype, cell 
viability assay and collagen degradation assay. 
Protease-indipendent invasion was evaluated by 
3D-Boyden chamber assays with Matrigel coating in 
the presence of a protease inhibitor cocktail, consisting 
of Ilomastat, leupeptin, pepstatin A, E-64 and aprotinin, 
a mixture of protease inhibitors with a broad specificity 
for serine, cysteine, aspartic and amino-peptidase, and 
Oncotarget1551www.impactjournals.com/oncotarget
MMPs [7]. Protease inhibitor cocktail was added to un-
polymerized Matrigel solution on the upper surface of 
the porous filter. To induce the amoeboid phenotype, 
cells were treated for 2 hours with the protease inhibitor 
cocktail at the same concentrations used in the invasion 
assay. The cocktail did not affect cell viability, as shown 
by WST-1 assay (Roche), performed as previously 
described [20]. 
The collagen degradation assay was performed 
using a Matrigel layer containing 3% FITC-labelled 
collagen monomers, as reported previously [7].
Cell migration in 3D-collagen matrices. 
To visualize the efficacy of the protease inhibitor 
cocktail to induce an amoeboid migration style we used 
reconstruction by time-lapse video microscopy and 
confocal microscopy, using HT1080 cells as a model for 
a clear visualization of fiber breakdown in the process of 
proteolytic migration and shift to the amoeboid style, as 
previously reported [7]. (SM 1 and 2).
RhoA and Rac1 activity assay.
Cells from different experimental conditions 
(control, protease inhibitor cocktail, anti-uPAR aODN 
and anti-uPAR aODN + protease inhibitor cocktail) 
were lysed in radioimmunoprecipitation assay buffer and 
determination of RhoA GTP or Rac1 GTP was performed 
as previously reported [7].   
Western Blotting. 
 The composition of the lysis buffer was as 
previously described [42]. The same lysis buffer was 
used to solubilise beads-adsorbed active forms. Both 
beads and cell proteins were subjected to Western blotting 
as previously reported [22]. The membrane was probed 
with primary antibody to uPAR, RhoA and Rac1 (Becton 
Dickinson), overnight at 4° C. Immune complexes were 
detected as previously reported [22]. 
Immunofluorescence analysis.
Immunofluorescence was performed as previously 
described [13,22]. Cells were grown on coverslips in their 
culture conditions. Once at confluence, cells were treated 
with protease inhibitor cocktail and Ilomastat. Two hours 
later TRITC-labelled phalloidin (P1951, Sigma) was 
applied to the cells to visualize cell morphology and  the 
arrangement of actin cytoskeleton. Nuclei were stained 
with the fluorescent Hoechst 33342 dye (DAPI) (10µg/
ml) (Invitrogen) for 15 min at rt. A single composite image 
was obtained by superimposition of twenty optical sections 
for each sample observed. The collected images were 
analysed by ImageJ software to evaluate co-localization. 
uPAR down-regulation with antisense 
oligodeoxinucleotide (u-PAR aODN). 
uPAR gene expression was inhibited with an 18-mer 
phosphorothioate aODN (ISIS Pharmaceuticals, Carlsbad 
Research Center, CA, USA, product designation: ISIS 
17916) as previously described [21]. 
Treatment of cells with  M25 peptide. 
Disruption of uPAR-integrin interaction was 
obtained with the M25 peptide, previously identified in 
a phage display library [42,48], able to uncouple uPAR 
interaction with integrin α-chain. The peptide was 
produced in collaboration with PRIMM srl, Milan, Italy. 
In the β-propeller model of α-chain folding, the sequence 
of this peptide (STYHHLSLGYMYTLN) spans an 
exposed loop on the ligand-binding surface of α-chain, 
thus impairing integrin-uPAR interaction. In cell culture 
both M25 and scramble-M25 (sM25) were used at 50 μM 
for 2h at 37°C. 
Statistical analysis.
Results are expressed as means ± SD. Multiple 
comparisons were performed by the Student test. 
Statistical significances were accepted at p<0.05.
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